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IntroductIon
Despite there have been significant pharmacological progresses and improvements in in-
dividual and community assistance, schizophrenia remains a disabling, chronic disease with 
alternating periods of remission and relapse. Since each subsequent relapse exacerbates the 
clinical deterioration of the patient, with consequent worsening of symptoms, progressive 
cognitive impairment, functioning deterioration, and reduced quality of life, one of the major 
goals of schizophrenia treatment is to prevent or delay relapse [1-5].
Long-acting injectable antipsychotics (LAIs) were introduced in clinical practice in the 
1960s with the aim of overcoming the limits associated with oral antipsychotics (OAPs) in 
terms of treatment adherence and pharmacokinetics profile [2-7].
Although the use of LAIs is considered an important option, in particular for patients with 
adherence problems [2,3,5,8], two recent meta-analyzes [9,10], which aimed to compare LAIs 
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AbstrAct
BACKGROUND: Although the use of long-acting injectable antipsychotics (LAIs) is considered an important option in 
the management of schizophrenia two recent meta-analysis, which aimed to compare LAIs vs oral antipsychotics (OAPs) 
in terms of relapse rate, showed discordant results.
AIM: To investigate factors affecting the efficacy of antipsychotics in terms of relapse prevention in the real-world and to 
estimate the management cost of an episode of relapse.
METHODS: We conducted a literature search using MEDLINE/PubMed with the aim to extract efficacy, effectiveness 
and adherence data of LAIs and OAPs. The primary outcome was the relative risk (RR) of relapse between two strategies. 
The extracted RR were included in a series of Bayesian statistical models based on the starting hypotheses. The RR rates 
obtained from the meta-analysis have been used as input for an economic evaluation of the total costs associated with the 
management of the patient with schizophrenia from the Italian NHS perspective.
RESULTS: The literature search identified 34 studies which met the inclusion criteria and were analyzed. According to the 
model that best explains the data, in the real-world setting the effectiveness with LAIs is greater than with OAPs, with a 
more pronounced effect for SGAs than for FGAs. Taking into account generation, route and frequency of administration, 
the RR decreased with lower administration frequency, with SGA LAI administered once every 90 days which is associated 
with the greatest reduction in the risk of relapse (-85%). When the results of the meta-analysis are used to feed an economic 
evaluation the results show that the SGA administered every 90 days is the strategy with the least expected cumulative cost 
both at 1 (€ 3,509) and 5 years (€ 19,690).
CONCLUSION: SGA LAIs administered every 90 days seems to be the best option for the treatment of patient with schizo-
phrenia from both the clinical and economic perspectives.
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vs OAPs in terms of relapse rate, showed discordant results between randomized clinical trials 
(RCTs) and mirror-image studies.
The first meta-analysis [10] included only RCTs lasting more than 6 months, which com-
pared LAIs and OAPs. The primary outcome was the relapse rate at the longest study time 
point; secondary outcomes included the relapse rate at specific time points (3, 6, 12, 18, 
and 24 months), all-cause discontinuation, discontinuation due to adverse events, drug inef-
ficacy, hospitalization and non-adherence. A total of 21 RCTs were included in the analysis 
and the results showed that, when pooled together, LAIs did not reduce relapse compared 
with OAPs. In particular, pooled LAIs only showed trend-level superiority over OAPs in 
preventing hospitalization (RR = 0.88; 95% CI: 0.78-1.02; p = 0.09) with a gradient related 
to the frequency of administration (longer intervals of administration were associated with 
a greater reduction of relapse rate) and pharmacological class (relapse rate with SGA was 
lower than with FGA).
Since the patients enrolled in RCTs are generally different from those in real-world stud-
ies in terms of adherence rate and illness severity, the second meta-analysis conducted by 
Kishimoto et al. [9] was based on 25 mirror-image studies, which better reflect the real-world 
setting. The study included mirror-image studies that compared period ≥ 6 months with OAPs 
and ≥ 6 months with LAIs in adults with schizophrenia and that reported information about 
hospitalization or relapse-related data. The primary outcomes were hospitalization risk and 
the total number of hospitalizations, while secondary outcomes included total hospitaliza-
tion days and length of stay. The results of this meta-analysis show a statistically significant 
superiority of LAIs over OAPs in preventing hospitalization (RR = 0.43, 95% CI: 0.35-0.53; 
p < 0.001) and decreasing the number of hospitalizations (RR = 0.38; 95% CI: 0.28-0.51; p 
< 0.001).
In the light of these results we conducted a comprehensive literature review and meta-an-
alyzed the retrieved data by use of a Bayesian hierarchical model, with the aim to investigate 
factors affecting the efficacy of antipsychotics in terms of relapse prevention in the real-world 
(effectiveness). The results of the meta-analysis have been used as input for an economic 
evaluation of the total costs associated with the management of the patient with schizophrenia 
from the Italian National Health System (NHS) perspective. Mean cumulative total cost per 
patient at 1 and 5 years, was calculated by antipsychotic treatment (first or second generation 
and administration frequency) and cost items (antipsychotic treatment and relapse manage-
ment).
Methods and input data have been reviewed and approved by an Italian expert board (see 
Acknowledgements).
Methods
Starting from the assumption that the antipsychotics effectiveness is a function of both 
their pharmacological and pharmacodynamics characteristics, on one side, and their use in 
real-world setting, on the other, a meta-analysis has been performed to test the following 
hypotheses:
1. In a real-world setting LAIs are associated with better adherence compared to OAPs;
2. In an experimental setting (RCT) a LAI and the same OAP have similar efficacy and ad-
herence while in the real-world a net increase in the efficacy of LAI can be noted;
3. This phenomenon has a gradient and it becomes more evident when the administration is 
less frequent.
Literature Search and Inclusion Criteria
We conducted a literature search using MEDLINE/PubMed (last access May 18, 2017) 
with the aim to extract efficacy, effectiveness and adherence data of LAIs and OAPs.
The search strings (one for the search of efficacy/effectiveness data and one for the search 
of adherence data) have been designed on the basis of the PICOS schema (Table I), as recom-
mended by the PRISMA guidelines [11].
Two independent investigators conducted the literature search; the revision and the selec-
tion of the studies were performed on the basis of title/abstract and then of the full-text. The 
electronic search through MEDLINE was supplemented by manual check of reference lists 
of included studies. Any disagreements were resolved by discussion or by the intervention of 
a third investigator.
PICOS component Inclusion criteria Exclusion criteria
Participants Adults with schizophrenia  • Other mental disorder
 • Acute phase
 • Drug resistance
 • Observational cohort studies < 50 patients
Intervention Oral or long-acting injectable monotherapy with 
risperidone, paliperidone, aripiprazole, olanzapine, 
haloperidol, fluphenazine, zuclopentixol
Any other treatment
Comparators All (head to head, placebo, other formulation, other 
or none)
-
Outcome  • Primary: relapse rate
 • Secondary: treatment adherence
Absence of adherence or relapse outcome
Study design  • Efficacy: interventional studies (RCT, nRCT, 
Uncontrolled Clinical Trial – UCT)
 • Effectiveness: observational studies (cohort 
longitudinal retrospective or prospective studies)
 • Adherence: observational studies (cohort 
longitudinal retrospective or prospective studies)
 • Review/meta-analyses
 • Case-report/case series
 • Preclinical studies
Other  • Out of objective (scope): evaluation of the 
effect of discontinuation therapy, switch, on-top/
augmentation strategies; methodological and 
pharmacokinetics studies
 • Post-hoc or subgroup analyzes
 • Unavailability of full-text
Table I. Inclusion and exclusion criteria
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Data Extraction and Data Analysis
The primary outcome was the relative risk (RR) of relapse between two strategies. There-
fore, we selected all the studies that compared two strategies differing in terms of active 
ingredient and/or administration route and/or inter-administration interval and extracted the 
adjusted relative risk (RR) from the text. When the relative risk was not reported, we esti-
mated it from reported data as the ratio between absolute rates.
For RCTs we relied on the efficiency of randomization in minimizing the risk of bias, and 
took no further action, while for observational studies, this was done only in case of cohorts 
matched on risk factors for relapse, or statistically equivalent in terms of baseline character-
istics. This implies that any observational study on mismatched cohorts did not contribute to 
the estimation of relative treatment effects.
The extracted relative risks were included in a series of Bayesian statistical models based 
on the starting hypotheses. In order to identify the hypothesis that best suited the data, three 
model sets based on alternative assumptions on the influence of administration were tested: 
route only, administration frequency only, or both.
For the effect of administration frequency on risk of relapse, proportional (RR depends on 
the ratio of frequencies) and additive (RR depends on the difference of frequencies) specifica-
tions were evaluated.
Finally, all model versions were evaluated with and without considering the generation of 
the AP (FGA vs. SGA).
For the relative effectiveness and economic outcome predictions, inference was based on 
the best model. This was identified by means of the Bayesian Information Criterion (BIC), 
which allows selecting the best model basing on goodness-of-fit and parsimony, with lower 
values indicating better performance.
The secondary outcome was the adherence, but the qualitative analysis of adherence data 
revealed extremely high heterogeneity in the measurement methods, in the outcomes and in 
the elaborations, in addition to poor reliability of the data for oral drugs. All these factors were 
judged to have a too high potential for bias to obtain a reliable result. For this reason adher-
ence data were excluded from the quantitative analysis.
Economic Evaluation
The relative relapse rates obtained from the meta-analysis have been used to feed an eco-
nomic evaluation of the total costs associated with the antipsychotic treatment over a time 
horizon of 1 and 5 years.
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Since the analysis was performed from 
the Italian NHS perspective, only direct costs 
were considered. Drug acquisition costs were 
calculated taking into account the treatment 
mix reported by IQVIA for Italy in 2017 [12], 
their maximum acquisition cost for the NHS, 
the adherence rate and the time horizon.
Weighted average ex-factory prices for 
each category are reported in Table II. They 
have been estimated starting from ex-factory 
price for drugs in class H or A included in 
the PHT list [13] and retail price for drugs in 
class A non-included in the PHT list [13], af-
ter weighting the contribution of the different 
dose levels to the total sales of a single brand, 
and then weighing brands belonging to the 
same categories by their respective patient 
shares, as reported by sales data in 2017 [12].
The adherence rate was estimated (for 
costing purposes only) at 50% for OAPs, 
which is an average from the literature data. 
Applying the odds ratios estimated by Pillon 
et al. [14], the adherence rate for first gen-
eration (71%) and second generation (82%) 
LAIs was calculated.
The relapse management cost was cal-
culated from the relapse rate by class and 
administration frequency obtained from the 
meta-analysis and the cost of managing an 
episode of relapse.
According to Expert opinion the cost of 
an episode of relapse was not only derived 
from the Diagnosis Related Group (DRG) 
tariff, which does not encompass the entire 
relapse management pathway, but it was cal-
culated taking into account both hospitalization and the subsequent stay in residential facili-
ties. In order to better represent the Italian context, the mean cost between Lazio, Lombardy, 
and Tuscany was used in the economic evaluation. The cost considered by the experts com-
prises the hospitalization for the acute phase for 10-15 days (proxied with the regional tariffs) 
and the following rehabilitation in a dedicated institution for a mean of 30 days: the resulting 
mean cost per relapse is € 10,500.
In the 5-year scenario every relapse increases the subsequent relapse rate by 20% [15,16].
results
Search and Study Characteristics
The literature search identified 546 studies, plus 39 studies added through manual check, 
for a total of 585 studies. Of these, 368 studies were excluded after the screening by title and 
abstract and 217 were fully inspected. Finally, 34 studies (20 RCTs) met the inclusion criteria 
and were analyzed (Figure 1). The details of the studies included are presented in Table III 
[17-50].
OAPs (€)
LAIs (€)
2-weekly 3-weekly Monthly 3-Monthly
FGA 7.9 - 14.8 10.5 -
SGA 30.2 269.6 - 287.3 287.3
Table II. Weighted average ex-factory prices
FGA OAP = haloperidol; SGA OAP = paliperidone, risperidone, olanzapine, 
aripiprazole; SGA 2-weekly = olanzapine, risperidone; FGA 3-weekly = fluphenazine; 
FGA monthly = haloperidol; SGA monthly = paliperidone, olanzapine, aripiprazole; 
SGA 3-monthly = assumed equal to SGA monthly
Figure 1. Flowchart of literature search
Reference Comparators Patients (n.)
Relative efficacy/
effectiveness
Data extracted
Observational studies [17-30]
Baser, 2015 PAL 30 vs. SGA OAPs 335 vs. 335 0.623 Ratio between absolute rates in propensity 
score matching
Bitter, 2013 RIS 14 vs. ARI oral 1095 vs. 601 0.640 Ratio between absolute rates in propensity 
score matching
Table continues >
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Reference Comparators Patients (n.)
Relative efficacy/
effectiveness
Data extracted
Bitter, 2013 RIS 14 vs. OLA oral 1095 vs. 1633 0.767 Ratio between absolute rates in propensity 
score matching
Bitter, 2013 RIS 14 vs. RIS oral 1095 vs. 2480 0.387 Ratio between absolute rates in propensity 
score matching
Grimaldi-Bensouda, 
2012
RIS 14 vs. OAPs 400 vs. 784 0.490 Adjusted RR from text
Guo, 2011 OLA oral vs. ARI oral 149 vs. 132 0.947 Ratio between absolute rates
Joshi, 2016 PAL 30 vs. RIS 14 499 vs. 499 0.720 Adjusted OR from text
Lafeuille, 2015 PAL 30 vs. OAPs 374 vs. 32475 0.750 HR from text
Marcus, 2015 FLU 14-42 vs. OAPs 45 vs. 3428 0.870 Adjusted OR from text
Marcus, 2015 ALO 28 vs. OAPs 112 vs. 3428 0.910 Adjusted OR from text
Marcus, 2015 RIS 14 vs. OAPs 81 vs. 3428 0.670 Adjusted OR from text
Marcus, 2015 PAL 30 vs. OAPs 102 vs. 3428 0.530 Adjusted OR from text
Morrato, 2015 PAL 30 vs. SGA OAPs 201 vs. 595 0.860 Adjusted OR from text
Ren, 2011 RIS 14 vs. OAPs 924 0.743 Ratio between absolute rates
Schreiner, 2014 RIS 14 vs. SGA OAPs 426 vs. 490 0.654 Ratio between absolute rates
Tiihonen, 2006 OLA oral vs. ALO oral 822 vs. 107 0.540 Adjusted RR from text
Tiihonen, 2006 RIS oral vs. ALO oral 651 vs. 107 0.890 Adjusted RR from text
Tiihonen, 2011 RIS 14 vs. RIS oral 51 vs. 411 0.570 Adjusted HR from text
Tiihonen, 2011 ZUC 14 vs. ZUC oral 30 vs. 6 0.490 Adjusted HR from text
Tiihonen, 2011 ALO 28 vs. ALO oral 6 vs. 9 0.120 Adjusted HR from text
Tiihonen, 2017 RIS 14 vs. RIS oral 3021 vs. 7016 0.859 Ratio between adjusted HR vs. no 
treatment from text
Tiihonen, 2017 ZUC 14 vs. ZUC oral 4083 vs. 3425 0.791 Ratio between adjusted HR vs. no 
treatment from text
Tiihonen, 2017 OLA 14 vs. OLA oral 400 vs. 1173 0.921 Ratio between adjusted HR vs. no 
treatment from text
Tiihonen, 2017 ALO 28 vs. ALO oral 1632 vs. 3348 0.790 Ratio between adjusted HR vs. no 
treatment from text
Voss, 2015 PAL 30 vs. OAPs 109 vs. 109 0.540 HR from text
RCT [31-50]
Alphs, 2015 PAL 30 vs. OAPs 226 vs. 218 0.681 Ratio between absolute rates
Buckley, 2014 RIS 14 vs. OAPs 146 vs. 150 1.285 Ratio between absolute rates
Carpenter, 1999 FLU 14 vs. FLU 42 25 vs. 25 0.763 Ratio between absolute rates
Csernansky, 2002 ALO oral vs. RIS oral 188 vs. 177 1.930 RR from text
Detke, 2014 OLA 28 vs. OLA oral 264 vs. 260 1.086 Ratio between absolute rates
Fleischhacker, 2014 ARI 28 vs. ARI oral 265 vs. 266 0.985 Ratio between absolute rates
Glick, 2002 OLA oral vs. ALO oral 541 vs. 158 0.828 Ratio between absolute rates
Hogarty, 1979 FLU 14 vs. FLU oral 27 vs. 25 0.862 Ratio between absolute rates
Ishigooka, 2015 ARI 28 vs. ARI oral 228 vs. 227 0.920 Ratio between absolute rates
Kane, 2009 OLA oral vs. ARI oral 281 vs. 285 0.985 Ratio between absolute rates
Kane, 2010 OLA 14 vs. OLA oral 281 vs. 322 1.500 Adjusted HR from text
Kane, 2010 OLA 28 vs. OLA oral 318 vs. 322 1.400 Adjusted HR from text
Kane, 2010 OLA 14 vs. OLA 28 281 vs. 318 1.000 Adjusted HR from text
Keks, 2007 RIS 14 vs. OLA oral 247 vs. 300 1.170 Ratio between absolute rates
Kim, 2008 RIS 14 vs. RIS oral 22 vs. 28 0.307 Ratio between absolute rates
Lieberman, 2005 OLA oral vs. RIS oral 330 vs. 333 0.575 Ratio between absolute rates
Malla, 2016 RIS 14 vs. OAPs 42 vs. 35 1.894 Ratio between absolute rates
McEvoy, 2014 PAL 30 vs. ALO 28 145 vs. 145 1.294 Ratio between absolute rates
Rosenheck, 2011 RIS 14 vs. OAPs 187 vs. 182 0.870 Adjusted HR from text
Savitz, 2016 PAL 90 vs. PAL 30 483 vs. 512 0.870 HR from text
Schooler, 1980 FLU 21 vs. FLU oral 107 vs. 107 0.668 Ratio between absolute rates
Schooler, 2005 RIS oral vs. ALO oral 197 vs. 203 0.864 Ratio between absolute rates
Table III. Details of the studies included in the meta-analysis
ALO = haloperidol; ARI = aripiprazole; FLU = fluphenazine; OAP = oral antipsychotics; OLA = olanzapine; 
PAL = paliperidone; RIS = risperidone; SGA = second generation antipsychotics; ZUC = zuclopentixol
> Table continued
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 - Common results of all tested models indicate that:
 - In real-world setting, the effectiveness is greater with LAIs than with orals– this effect is 
more pronounced for SGAs than for FGAs, while the route has no statistically significant 
effect under experimental conditions;
 - In real-world settings the effectiveness significantly increases with decreasing administra-
tion frequency;
There are high probabilities (80-95% in the best fitting models) that the intrinsic efficacy 
of SGAs is greater than that of FGAs.
The model best explaining the data was the one that comprises both the effect of route 
and frequency of administration (additive effect) and that considers a class effect (FGAs vs. 
SGAs) for both intrinsic efficacy and administration route effect (Table IV).
 - According to this model:
 - In the real world setting, a LAI reduces the risk of relapse, compared to the same AP given 
by the oral route, by 20% (RR = 0.8) if it belongs to the first generation, and by almost 
50% (RR = 0.53) if a SGA;
 - In the real world setting, the risk of relapse is reduced by 10% (RR = 0.9) for each addi-
tional week of inter-dose interval;
Second generation agents reduce the risk of relapse by almost 20% (RR = 0.79) when 
compared to FGAs of equivalent route and frequency of administration. 
Figure 2 shows the relative risks (vs. FG OAP, taken as reference) for all considered com-
binations of generation, route, and frequency of administration inferred by the model. As can 
be seen, relapse rate decreased with lower administration frequency, and the greatest reduc-
tion in the risk of relapse is expected with the use of a SGA LAI administered once every 90 
days, associated with an estimated RR of 16%, i.e. a reduction of 84% in the frequency of 
relapse, compared to the use of an oral, first generation, antipsychotic agent.
Credibility of results (i.e. posterior probability of superiority, measured as percentage of 
iterations with RR < 1 - data not shown) resulted close to certainty (98-100%) for the com-
parison of any LAI vs. any OAP, while there is substantial uncertainty in the comparison of 
oral SGAs versus first generation LAIs.
Treatment effect FgA: LAIs vs. OAPs SgA: LAI vs. OAPs SgA vs. FgA +7 days1
RR [95% CI] 0.80 [0.69-0.93] 0.53 [0.48-0.58] 0.79 [0.58-1.09] 0.90 [0.80-1.00]
Credibility2 (%) 99.8 100 93.4 97.2
Table IV. Best model results (real-world)
1 Each additional 7 days of inter-dose interval
2 Posterior probability of superiority, measured as percentage of iterations with RR < 1
Figure 2. Relapse rate reduction vs oral FGA according to class and administration frequency
Administration 
frequency
Total cost per patient (€)
1 year 5 years
FgA SgA FgA SgA
Daily 6,086 [4,112-8,472] 4,753 [3,425-6,332] 45,180 [30,480-62,950] 34,930 [25,060-46,670]
2-weekly NA 5,085 [4,285-6,064] NA 31,370 [25,590-38,570]
3-weekly 4,493 [2,793-6,697] NA 33130 [20460-49520] NA
Monthly 4,022 [2,380-6,196] 4,786 [4,085-5,643] 29710 [17480-45870] 28,720 [23,670-34,930]
3-monthly NA 3,795 [3,045-5,275] NA 21,270 [15,940-32,350]
Table V. Mean [95% CrI] cumulative total cost per patient at 1 and 5 years, by antipsychotic treatment
Administration 
frequency
Probability SgA 90-day less costly (mean delta) vs.
FgA SgA FgA SgA
After 1 year After 5 years
Daily 98% (2,291 €) 87% (958 €) 100% (23,910 €) 97% (13,660 €)
2-weekly 96% (1,290 €) 96% (10,100 €)
3-weekly 77% (698 €) 97% (11,860 €)
Monthly 58% (227 €) 97% (991 €) 93% (8,440 €) 97% (7,450 €)
Table VI. Probability that the cumulative total cost per patient of alternative strategies is higher than SGA 90-day at 1 and 5 years, and 
their mean cost increase
Figure 3. Mean cumulative total cost per patient at 1 and 5 years, by antipsychotic treatment and cost items
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relapse, compared to the use of an oral, first generation, antipsychotic agent.
Credibility of results (i.e. posterior probability of superiority, measured as percentage of 
iterations with RR < 1 - data not shown) resulted close to certainty (98-100%) for the com-
parison of any LAI vs. any OAP, while there is substantial uncertainty in the comparison of 
oral SGAs versus first generation LAIs.
Treatment effect FgA: LAIs vs. OAPs SgA: LAI vs. OAPs SgA vs. FgA +7 days1
RR [95% CI] 0.80 [0.69-0.93] 0.53 [0.48-0.58] 0.79 [0.58-1.09] 0.90 [0.80-1.00]
Credibility2 (%) 99.8 100 93.4 97.2
Table IV. Best model results (real-world)
1 Each additional 7 days of inter-dose interval
2 Posterior probability of superiority, measured as percentage of iterations with RR < 1
Figure 2. Relapse rate reduction vs oral FGA according to class and administration frequency
Administration 
frequency
Total cost per patient (€)
1 year 5 years
FgA SgA FgA SgA
Daily 6,086 [4,112-8,472] 4,753 [3,425-6,332] 45,180 [30,480-62,950] 34,930 [25,060-46,670]
2-weekly NA 5,085 [4,285-6,064] NA 31,370 [25,590-38,570]
3-weekly 4,493 [2,793-6,697] NA 33130 [20460-49520] NA
Monthly 4,022 [2,380-6,196] 4,786 [4,085-5,643] 29710 [17480-45870] 28,720 [23,670-34,930]
3-monthly NA 3,795 [3,045-5,275] NA 21,270 [15,940-32,350]
Table V. Mean [95% CrI] cumulative total cost per patient at 1 and 5 years, by antipsychotic treatment
Administration 
frequency
Probability SgA 90-day less costly (mean delta) vs.
FgA SgA FgA SgA
After 1 year After 5 years
Daily 98% (2,291 €) 87% (958 €) 100% (23,910 €) 97% (13,660 €)
2-weekly 96% (1,290 €) 96% (10,100 €)
3-weekly 77% (698 €) 97% (11,860 €)
Monthly 58% (227 €) 97% (991 €) 93% (8,440 €) 97% (7,450 €)
Table VI. Probability that the cumulative total cost per patient of alternative strategies is higher than SGA 90-day at 1 and 5 years, and 
their mean cost increase
Figure 3. Mean cumulative total cost per patient at 1 and 5 years, by antipsychotic treatment and cost items
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Economic Evaluation
The average (95% CrI) cumulative 1 year and 5 year cost for the management of a patient 
with schizophrenia estimated by the model for the available strategies are shown in Table V.
The data indicate that the strategy with the least expected cumulative cost is SGA adminis-
tered every three months, already at one year, and more so in the medium term (5 years), with 
91% (data not shown) chances of being the least costly strategy (Table VI).
Observing the contribution of the single cost items to the total (Figure 3), it can be seen 
how the component related to the drug acquisition becomes more prevalent moving from the 
least to the most effective treatments, and how this trend becomes more evident with longer 
time horizons.
dIscussIon
Long-acting injectable antipsychotics (LAIs) were introduced in the treatment of schizo-
phrenia with the aim of improving treatment adherence and pharmacokinetics profile associ-
ated with OAPs.
Our meta-analysis, which aimed to investigate factors affecting the efficacy of antipsy-
chotics in terms of relapse prevention in the real-world (effectiveness), shows that in the real-
world setting the effectiveness with LAIs is greater than with OAPs, with a more pronounced 
effect for SGAs than for FGAs. In particular, a LAI reduced the risk of relapse by 20% and 
50%, as compared to the same AP given by oral route and belonging to the first and the second 
generation, respectively. Furthermore, in the real-world setting the effectiveness significantly 
increases with decreasing administration frequency, with a relative reduction in the risk of 
relapse equal to 10% for each additional week of inter-dose interval. Taking into account 
generation, route and frequency of administration our results show that, taking FGA OAP 
as reference, the relapse rate decreased with lower administration frequency, with SGA LAI 
administered once every 90 days which is associated with the greatest reduction in the risk of 
relapse (-84%). As shown in Table III, only one RCT that compares 90-day LAI was included 
in the meta-analysis [48]. This trial involved 1016 patients who were randomly assigned to 
90-day paliperidone or 30-day paliperidone and showed noninferiority of the 3-month formu-
lation in terms of relapse rate. The results demonstrated the noninferiority of the 3-monthly 
administration in terms of relapse rate and the mITT analysis showed that the nominal hazard 
ratio for a patients switching from 90-day (n = 483) to 30-day (n = 512) formulation was 0.87 
(95% CI: 0.56-1.34).
When the results of the meta-analysis are used to feed an economic evaluation, in order to 
estimate the management cost of an episode of relapse, the results show that the SGA admin-
istered every 90 days is the strategy with the least expected cumulative cost at 1 and 5 years 
(€ 3,795 and € 21,270, respectively).
Observing the composition of the single cost items (relapse management and drug cost) it 
can be seen that the cost for relapse management decreases moving from the daily adminis-
tration to less frequent administration schedules. Furthermore, even if the component related 
to the drug acquisition becomes more prevalent moving from the least to the most effective 
treatment, the clinical advantage in terms of relapse prevention compensates the drug cost, 
resulting in a lower total expenditure.
Our conclusions are in line with a recent systematic review, which aimed to investigate 
the economic impact of schizophrenia on the healthcare system in Europe and to identify the 
most important cost driver in the management of schizophrenia [51]. According to Kovacs et 
al. the component related to the hospital stay represents the major direct cost of schizophrenia, 
accounting for 27% to 92% of total direct medical costs, depending on the country considered. 
Among the suggestions given by the Authors in order to reduce the economic burden associ-
ated with schizophrenia and to improve the allocation of financial resources, there are the re-
duction of the number of hospitalizations and the improvement of persistence and adherence 
in antipsychotic therapy [51].
At the light of these results, it can be said that more efforts are needed in order to improve 
the management of patients with schizophrenia and to enhance identification of patients who 
can benefit most from the treatment with LAIs achieving better clinical and economic out-
comes.
The main limitation of our study is the inclusion in the meta-analysis of only one trial 
that compares 90-day vs. 30-day administration, however, due to the structure of the model, 
comparing strategies with differing administration frequency, provide information about the 
effect of the extension of the administration interval.
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conclusIon
Since one of the major goal of the treatment of schizophrenia is to prevent/delay relapse, 
at the light of our results SGA LAIs administered every 90 days seems to be the best option 
from both the clinical and economic perspectives.
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